MX2016014780A - Metodos y composiciones de dasotralina para el tratamiento del adhd. - Google Patents

Metodos y composiciones de dasotralina para el tratamiento del adhd.

Info

Publication number
MX2016014780A
MX2016014780A MX2016014780A MX2016014780A MX2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A MX 2016014780 A MX2016014780 A MX 2016014780A
Authority
MX
Mexico
Prior art keywords
dasotraline
adhd
treatment
compositions
methods
Prior art date
Application number
MX2016014780A
Other languages
English (en)
Inventor
D Loebel Antony
S Koblan Kenneth
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of MX2016014780A publication Critical patent/MX2016014780A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación y regímenes de tratamiento que emplean dasotralina para tratar el Trastorno por Déficit de Atención con Hiperactividad (ADHD). Las composiciones descritas en el presente documento no exhiben potencial de abuso.
MX2016014780A 2014-05-13 2015-05-12 Metodos y composiciones de dasotralina para el tratamiento del adhd. MX2016014780A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992588P 2014-05-13 2014-05-13
PCT/US2015/030342 WO2015175514A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd

Publications (1)

Publication Number Publication Date
MX2016014780A true MX2016014780A (es) 2017-07-25

Family

ID=54480544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014780A MX2016014780A (es) 2014-05-13 2015-05-12 Metodos y composiciones de dasotralina para el tratamiento del adhd.

Country Status (10)

Country Link
US (1) US20170266133A1 (es)
EP (1) EP3142999A4 (es)
JP (1) JP2017515858A (es)
KR (1) KR20170003677A (es)
CN (1) CN106660936A (es)
AU (1) AU2015259337A1 (es)
CA (1) CA2948829A1 (es)
IL (1) IL248846A0 (es)
MX (1) MX2016014780A (es)
WO (1) WO2015175514A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200405867A1 (en) * 2018-01-19 2020-12-31 Sunovion Pharmaceuticals Inc. Oral dosage forms
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
WO2004024669A1 (en) * 2002-09-16 2004-03-25 Sepracor, Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
DK2506842T3 (en) * 2009-12-04 2015-02-23 Sunovion Pharmaceuticals Inc Formulations, salts and polymorphs of transnorsertraline and their applications
EP2707000A4 (en) * 2011-05-13 2014-11-26 Dainippon Sumitomo Pharma Co TREATMENT AND CONTROL OF CNS DISORDERS

Also Published As

Publication number Publication date
EP3142999A4 (en) 2017-12-27
EP3142999A1 (en) 2017-03-22
CA2948829A1 (en) 2015-11-19
WO2015175514A1 (en) 2015-11-19
KR20170003677A (ko) 2017-01-09
AU2015259337A1 (en) 2016-12-08
CN106660936A (zh) 2017-05-10
IL248846A0 (en) 2017-01-31
JP2017515858A (ja) 2017-06-15
US20170266133A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
GB2541571A (en) Pharmaceutical compositions
IL253979A0 (en) Methods, preparations and kits for cancer treatment
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
IL251028A0 (en) 17a,21-diesters of cortexolone for use in the treatment of tumors
MX385594B (es) Administracion y dosificacion de diaminofenotiazinas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
IL252011A0 (en) Methods and compositions especially for the treatment of attention deficit disorder
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
TW201613587A (en) Medical treatments based on anamorelin
MX379622B (es) Compuestos espirociclicos
PH12017501864A1 (en) Compositions and methods for treating autism
PH12017500602A1 (en) Methods for treating ocular conditions
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EP4480577A3 (en) Structured elements and methods of use
PH12016501838A1 (en) Compounds and their methods of use
MX2017007027A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson.
MX2016014780A (es) Metodos y composiciones de dasotralina para el tratamiento del adhd.